Abstract 144P
Background
Patients with squamous NSCLC have a poorer prognosis than those with non-squamous histology and fewer treatment options. The phase 3 EMPOWER-Lung 1 study (NCT03088540) has demonstrated significant survival benefits of first-line (1L) cemiplimab monotherapy vs chemotherapy and an acceptable safety profile in patients with treatment-naïve squamous or non-squamous NSCLC with PD-L1 expression ≥50% and no EGFR, ALK or ROS1 aberrations. Here, we report 5-year results of patients with squamous NSCLC from this study.
Methods
In EMPOWER-Lung 1, patients were randomized to cemiplimab 350 mg IV every 3 weeks for 2 years or to investigator’s choice of chemotherapy. Primary endpoints were overall survival (OS) and progression-free survival (PFS) per Blinded Independent Review Committee. In this exploratory subgroup analysis, efficacy and safety were assessed for the subgroup of patients with squamous NSCLC. The data cutoff date was 16 January 2024 (median follow-up of 59.6 months for the overall study population).
Results
Of 565 patients with verified PD-L1 ≥50%, 245 (43%) had squamous NSCLC (cemiplimab: n = 123; chemotherapy: n = 122). Baseline characteristics were similar between treatment groups. At 5-year follow-up, cemiplimab resulted in longer OS (median 22.7 mo vs 13.5 mo; HR=0.51) and PFS (median 8.3 mo vs 5.9 mo; HR=0.44) vs chemotherapy (Table). Estimated 5-year survival probability was 25.5% for cemiplimab vs 6.9% for chemotherapy. Objective response rate (ORR) was significantly improved with cemiplimab (43.9% vs 22.1%). Approximately 42% of patients in both treatment groups had treatment-emergent adverse events (TEAEs) ≥ grade 3 (Table). Table: 144P
Cemiplimab (n=123)† | Chemotherapy (n=122)† | |
Clinical outcomes | ||
OS median (95% CI), mo | 22.7 (17.3–31.5) | 13.5 (10.0–16.2) |
HR (95% CI) | 0.51 (0.38–0.69)* | |
5-year probability OS, % (95% CI) | 25.5 (17.3–34.5) | 6.9 (2.8–13.6) |
PFS median (95% CI), mo | 8.3 (5.6–9.4) | 5.9 (4.5–6.2) |
HR (95% CI) | 0.44 (0.32–0.60)* | |
ORR, % (95% CI) | 43.9 (35.0–53.1) | 22.1 (15.1–30.5) |
Safety outcomes‡ | ||
TEAEs of any grade, n (%) | 110 (90.2) | 111 (94.1) |
Grade ≥3 TEAEs, n (%) | 51 (41.8) | 50 (42.4) |
†Subgroup from the PD-L1 ≥50% population. ‡Safety analysis set for the subgroup: cemiplimab (n=122), chemotherapy (n=118). ∗P<0.0001
Conclusions
At 5-year follow-up, 1L cemiplimab monotherapy continued to show durable clinical benefits vs chemotherapy in patients with squamous NSCLC.
Clinical trial identification
NCT03088540.
Editorial acknowledgement
Editorial support was provided by Fiona Woodward, of Alpha (a division of Prime, Knutsford, UK) funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
A. Baramidze: Financial Interests, Personal, Other, Travel support: Regeneron Pharmaceuticals, Inc. A. Sezer: Financial Interests, Institutional, Research Funding: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. K.D. Penkov: Financial Interests, Personal, Other, Honoraria: AstraZeneca, BeiGene, GSK, H3 Biomedicine, Janssen, Nektar, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi. M. Ozguroglu: Financial Interests, Personal, Other, Honoraria: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Personal, Advisory Board: Janssen, Sanofi, Astellas; Financial Interests, Personal, Other, Travel support: Bristol Myers Squibb, Janssen, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. E. Kalinka: Financial Interests, Personal, Other, Travel and accommodation support: Regeneron Pharmaceuticals, Inc. C. Zhu, F. Seebach, E. Kim, H. Magnan, J. Pouliot: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract